|
AP9528a-ev
|
Abcepta, Inc.
|
CHMP4B [N-term] [RB24088], Rabbit Polyclonal Antibody
|
Human
|
FC, IHC-P, WB
|
|
|
AP9528a
|
Abcepta, Inc.
|
CHMP4B [N-term] [RB24088], Rabbit Polyclonal Antibody
|
Human
|
FC, IHC-P, WB
|
|
|
AP8666b-ev
|
Abcepta, Inc.
|
DSC1 [C-term] [RB21405], Rabbit Polyclonal Antibody
|
Human
|
FC, WB
|
|
|
AP8666b
|
Abcepta, Inc.
|
DSC1 [C-term] [RB21405], Rabbit Polyclonal Antibody
|
Human
|
FC, WB
|
|
|
AP16771b-ev
|
Abcepta, Inc.
|
DSC3 [C-term] [RB35307], Rabbit Polyclonal Antibody
|
Human
|
WB
|
|
|
AP16771b
|
Abcepta, Inc.
|
DSC3 [C-term] [RB35307], Rabbit Polyclonal Antibody
|
Human
|
WB
|
|
|
AP8102c-ev
|
Abcepta, Inc.
|
TLK2 [Centre] [RB3046], Rabbit Polyclonal Antibody
|
Human, Mouse
|
WB
|
|
|
AP8102c
|
Abcepta, Inc.
|
TLK2 [Centre] [RB3046], Rabbit Polyclonal Antibody
|
Human, Mouse
|
WB
|
|
|
HY-P9968-1mg
|
MedChemexpress LLC
|
Nimotuzumab [CAS 780758-10-3]
|
|
Cancer-Kinase/protease
|
|
|
HY-P9968-5mg
|
MedChemexpress LLC
|
Nimotuzumab [CAS 780758-10-3]
|
|
Cancer-Kinase/protease
|
|
|
HY-P99770-1mg
|
MedChemexpress LLC
|
Omodenbamab [CAS 2241724-48-9]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99770-10mg
|
MedChemexpress LLC
|
Omodenbamab [CAS 2241724-48-9]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99770-5mg
|
MedChemexpress LLC
|
Omodenbamab [CAS 2241724-48-9]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99406-1mg
|
MedChemexpress LLC
|
Petosemtamab [CAS 2213450-26-9]
|
|
Cancer-Kinase/protease
|
|
|
HY-P99406-10mg
|
MedChemexpress LLC
|
Petosemtamab [CAS 2213450-26-9]
|
|
Cancer-Kinase/protease
|
|
|
HY-P99406-5mg
|
MedChemexpress LLC
|
Petosemtamab [CAS 2213450-26-9]
|
|
Cancer-Kinase/protease
|
|
|
HY-P99156-1mg
|
MedChemexpress LLC
|
Relatlimab [CAS 1673516-98-7]
|
|
Cancer-programmed cell death
|
|
|
HY-P99156-10mg
|
MedChemexpress LLC
|
Relatlimab [CAS 1673516-98-7]
|
|
Cancer-programmed cell death
|
|
|
HY-P99156-5mg
|
MedChemexpress LLC
|
Relatlimab [CAS 1673516-98-7]
|
|
Cancer-programmed cell death
|
|
|
HY-P99962-1mg
|
MedChemexpress LLC
|
Surzebiclimab
|
|
Cancer-programmed cell death
|
|
|
HY-P99962-10mg
|
MedChemexpress LLC
|
Surzebiclimab
|
|
Cancer-programmed cell death
|
|
|
HY-P99962-5mg
|
MedChemexpress LLC
|
Surzebiclimab
|
|
Cancer-programmed cell death
|
|
|
HY-P99395-1mg
|
MedChemexpress LLC
|
Talacotuzumab [CAS 1826831-79-1]
|
|
Cancer-programmed cell death
|
|
|
HY-P99575-1mg
|
MedChemexpress LLC
|
Tarlatamab [CAS 2307488-83-9]
|
|
|
|
|
HY-P99575-5mg
|
MedChemexpress LLC
|
Tarlatamab [CAS 2307488-83-9]
|
|
|
|
